Revenue increased 28% to $24.7 million compared to $19.4 million for the prior year period. Tissue-based tests accounted for 81% and 76% of total fourth quarter 2024 and 2023 revenue, respectively ...

Peter A. Thompson, a director at Sionna Therapeutics , Inc. (NASDAQ:SION), has made significant stock acquisitions as reported in a recent SEC filing. Thompson purchased 550,000 ...

These initiatives are expected to enhance Healios' capabilities in regenerative medicine, supported by collaborations with prominent investors like Athos Capital Limited and OrbiMed Advisors LLC.

Interest expense increased approximately $4.2 million in comparison to the prior year due to the interest expense incurred from the long-term debt of $40.0 million under the OrbiMed Credit Agreement.

PRINCETON, N.J., Feb. 12, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically ...

Overland Advantage, a business development company with a differentiated direct lending approach that benefits from a strategic relationship between Centerbridge Partners and Wells Fargo, announced ...

Ayala-led ACEN Corp. announced Tuesday, Feb. 4, that it has increased its stake in its subsidiary, Belenos Energy Corporation, to bolster its renewable energy (RE) portfolio. In a disclosure to the ...

Pursuant to the to the Agreement, OrbiMed agreed to provide a term loan facility in an aggregate principal amount of $50 million. The $10 million drawdown became available to TriSalus upon ...

28 January 2025 The headline payment percentage for newer medicines under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG) has been set at 22.9% for 2025, raising concerns from the ...